Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early tirofiban for no-reflow after endovascular therapy in acute anterior-circulation large-vessel ischemic stroke
ChiCTR2400080004Phase 4Not yet recruiting
- Sponsor
- Wuhan No.1 Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirofiban and aspirin in ischemic stroke (2 arms), sponsored by Wuhan No.1 Hospital. Primary endpoint: Modified Rankin Scale at 90 days after EVT. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
tirofibanaspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400080004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080004.